RT Journal Article
SR Electronic
T1 Hepatocellular Carcinoma With Extensive Cancer-associated Thrombosis Successfully Treated With Liver Resection and Direct Oral Anticoagulant: A Case Report
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6465
OP 6471
DO 10.21873/anticanres.14668
VO 40
IS 11
A1 KENSUKE YAMAMURA
A1 TORU BEPPU
A1 KOICHI KINOSHITA
A1 ERI ODA
A1 NOBUTAKA SATO
A1 HIDEAKI YUKI
A1 TOSHIHIKO MOTOHARA
A1 HIDEAKI MIYAMOTO
A1 HIDETOSHI KAWAGUCHI
A1 YOSHIHIKO KOMOHARA
A1 SHINICHI AKAHOSHI
YR 2020
UL http://ar.iiarjournals.org/content/40/11/6465.abstract
AB Aim: To assess the utility of the perioperative use of direct oral anticoagulants for patients with hepatocellular carcinoma (HCC) with cancer-associated thrombosis. Case Report: An 83-year-old woman was admitted with a solitary HCC (10-cm diameter), as well as with multiple sites of venous thromboembolism and macroscopic portal vein tumor thrombosis. She had appropriate liver function without viral hepatitis, triple-positive tumor markers, and secondary polycythemia. Edoxaban at 30 mg was initiated 10 days before surgery to remove HCC. Complete remission of the pulmonary embolism and stability of the deep vein thrombosis and massive superior mesenteric vein thrombosis were recognized preoperatively. An extended left hepatectomy was successfully performed. To avoid hemorrhage complications, we used intravenous administration of nafamostat mesylate for 2 days, thereafter we restarted edoxaban. Superior mesenteric vein thrombosis resolved 5 months after surgery. Conclusion: Perioperative oral administration of edoxaban was useful in multidisciplinary treatment for a patient with advanced HCC with cancer-associated thrombosis.